2020
Who is at risk of 13-valent conjugated pneumococcal vaccine failure?
Yildirim M, Keskinocak P, Pelton S, Pickering L, Yildirim I. Who is at risk of 13-valent conjugated pneumococcal vaccine failure? Vaccine 2020, 38: 1671-1677. PMID: 31974018, DOI: 10.1016/j.vaccine.2019.12.060.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseVaccine failureIPD casesVaccine serotypesDiagnosis of IPDHigh vaccine coverage ratesPneumococcal conjugate vaccineVaccine coverage ratesUnderlying risk factorsYears of ageMonths of agePneumococcal pneumoniaImmunization PracticesVaccine scheduleConjugate vaccinePneumococcal diseasePrimary dosesClinical presentationImmunization scheduleSerotype 19ACourse of immunisationRisk factorsComorbiditiesStudy periodPassive surveillance
2019
Assessment and Validation of Syndromic Case Definitions for Respiratory Syncytial Virus Infections in Young Infants: A Latent Class Analysis.
Lalani K, Yildirim I, Phadke VK, Bednarczyk RA, Omer SB. Assessment and Validation of Syndromic Case Definitions for Respiratory Syncytial Virus Infections in Young Infants: A Latent Class Analysis. The Pediatric Infectious Disease Journal 2019, 38: 1177-1182. PMID: 31568250, DOI: 10.1097/inf.0000000000002468.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSyndromic case definitionsCase definitionYoung infantsWorld Health OrganizationRSV infectionLatent class analysisPredictive valueLaboratory-confirmed RSV infectionRespiratory syncytial virus infectionSyncytial virus infectionAcute respiratory infectionsHigh positive predictive valueRoutine clinical careStandardized case definitionsHigh-resource settingsAppropriate case definitionsHigh-income settingsNegative predictive valueMonths of agePositive predictive valueRespiratory infectionsVaccine evaluationClinical featuresPediatric morbidity
2018
2354. Performance of Novel Clinical Case Definitions for Respiratory Syncytial Virus Infections in Young Infants: A Latent Class Analysis
Lalani K, Yildirim I, Phadke V, Bednarczyk R, Omer S. 2354. Performance of Novel Clinical Case Definitions for Respiratory Syncytial Virus Infections in Young Infants: A Latent Class Analysis. Open Forum Infectious Diseases 2018, 5: s700-s701. PMCID: PMC6255342, DOI: 10.1093/ofid/ofy210.2007.Peer-Reviewed Original ResearchRespiratory syncytial virusLaboratory-confirmed RSV infectionAcute respiratory infectionsCase definitionNegative predictive valueWorld Health OrganizationRSV infectionNovel RSV therapeuticsRoutine clinical careLatent class analysisHigh-resource settingsAppropriate case definitionsMonths of ageRSV therapeuticsRespiratory infectionsClinical featuresPediatric morbiditySyncytial virusDisease burdenClinical careChild healthcarePredictive valueYoung infantsMajor causeHealth Organization
2017
A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primaryand booster vaccination of healthy Turkish infants and toddlers*
Ceyhan M, Yıldırım İ, Tezer H, Devrim İ, Feroldi E. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primaryand booster vaccination of healthy Turkish infants and toddlers*. Turkish Journal Of Medical Sciences 2017, 47: 1247-1256. PMID: 29156870, DOI: 10.3906/sag-1609-62.Peer-Reviewed Original ResearchDTaP-IPVHB-PRPT vaccineT-BoostersPrimary seriesAnti-HBs seroprotectionLiquid DTaP-IPVT hexavalent vaccineOpen-label trialMIU/mLMonths of ageHealthy Turkish infantsAntibody persistenceBooster responseBooster vaccinationHB vaccinationControl vaccineHexavalent vaccineSeroconversion ratesTurkish infantsSeroprotectionVaccinePhase IIIParental reportsNoninferiority